Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the clinical development and ...

An antisense oligonucleotide demonstrated a favorable safety profile and its disease-halting effect in one patient suggests ...

CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

We’ve entered an era where biometric identity is currency. Regeneron just cornered a market without asking the public, the ...